Tenaya Therapeutics, Inc.
TNYA
$0.4111
-$0.0028-0.68%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.78% | -30.50% | -18.75% | -5.25% | 7.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -18.43% | -21.61% | -13.61% | -12.20% | 0.12% |
| Operating Income | 18.43% | 21.61% | 13.61% | 12.20% | -0.12% |
| Income Before Tax | 16.64% | 20.37% | 12.04% | 11.54% | -1.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.64% | 20.37% | 12.04% | 11.54% | -1.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.64% | 20.37% | 12.04% | 11.54% | -1.55% |
| EBIT | 18.43% | 21.61% | 13.61% | 12.20% | -0.12% |
| EBITDA | 21.29% | 22.90% | 14.37% | 12.79% | -0.04% |
| EPS Basic | 38.57% | 31.71% | 24.53% | 24.24% | 8.34% |
| Normalized Basic EPS | 38.56% | 31.72% | 24.55% | 24.25% | 8.36% |
| EPS Diluted | 38.57% | 31.71% | 23.90% | 24.24% | 8.34% |
| Normalized Diluted EPS | 38.56% | 31.72% | 24.55% | 24.25% | 8.36% |
| Average Basic Shares Outstanding | 35.67% | 16.61% | 16.55% | 16.77% | 10.79% |
| Average Diluted Shares Outstanding | 35.67% | 16.61% | 16.55% | 16.77% | 10.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |